Outcome of Board Meeting held today i.e., October 31, 2025 for the quarter and half year ended September 30…

We are taking steps to mitigate that in terms of, one, the retention bonus plan, which we had has been stopped effective 1st of March.

From quarter 4 to quarter 1, which is a sequential quarter, we had an impact on the margin of around 100 basis points because of the private label mix.

Absolutely, we aspire to recover as much as possible on the 100 bps impact on the gross margins due to private label, but that will be over a period of a couple of quarters.

Initially, we should see a comeback on the non-pharma and a bit on pharma.

On membership alone, we should see a INR10 crores to INR11 crores impact on the top line for the whole year, which will flow through to the bottom line.

On a full year basis, as I had earlier mentioned, request you to be a bit patient, allow us a quarter, let us reassess the situation, and we will be in a better position to guide or even articulate what would be the full year numbers.